Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

PubWeight™: 0.85‹?›

🔗 View Article (PMC 4262153)

Published in J Hepatol on April 05, 2014

Authors

Dana D Byrne1, Craig W Newcomb2, Dena M Carbonari3, Melissa S Nezamzadeh3, Kimberly B F Leidl2, Maximilian Herlim2, Yu-Xiao Yang1, Sean Hennessy3, Jay R Kostman4, Mary B Leonard5, A Russell Localio2, Vincent Lo Re6

Author Affiliations

1: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
2: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
3: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
4: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5: Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatrics, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
6: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: vincentl@mail.med.upenn.edu.

Articles cited by this

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43

Chronic hepatitis B. Hepatology (2007) 13.75

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18

Matching methods for causal inference: A review and a look forward. Stat Sci (2010) 9.78

Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05

Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48

Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med (2002) 4.38

Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health (1999) 3.55

Identification of fractures from computerized Medicare files. J Clin Epidemiol (1992) 3.26

Epidemiology and natural history of hepatitis B. Semin Liver Dis (2005) 3.25

Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med (2011) 2.94

The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis (2010) 2.52

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One (2011) 2.11

Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc (2007) 2.01

Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem (2001) 1.99

AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89

Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis (2011) 1.83

Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care (2007) 1.66

Racial differences in fracture risk. Epidemiology (1994) 1.54

Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis (2004) 1.54

Beta-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem (2006) 1.46

Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res (2012) 1.44

Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop Relat Res (2011) 1.40

Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf (2003) 1.38

Hepatic osteodystrophy. Hepatology (2001) 1.37

Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol (2005) 1.37

Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.24

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16

Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens (2004) 1.11

Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab (2004) 1.09

Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS (2009) 1.04

Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk. Aliment Pharmacol Ther (2012) 1.03

Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cyclooxygenase-2. J Immunol (2011) 1.02

Bone disease in cholestatic liver disease. Gastroenterology (1995) 0.98

Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis (2013) 0.93

Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007. Ann Epidemiol (2014) 0.91

Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma. Eur J Gastroenterol Hepatol (1997) 0.90

Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol (1994) 0.88

Chronic viral hepatitis is associated with low bone mineral density in HIV-infected patients, ANRS CO 3 Aquitaine Cohort. J Acquir Immune Defic Syndr (2013) 0.80

In the eye of the B-holder: natural history of chronic hepatitis B. Hepatology (2013) 0.76